Tag Archives: entrepreneurship

Investor Panels at RESI Boston September

24 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston returns on September 17, 2025 at the Westin Copley Place, once again serving as a core event during Biotech Week Boston. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together life science and healthcare companies with hundreds of investors and strategic partners for a day of partnering, networking, educational content, and exhibits.

A highlight of every RESI conference is the investor panel programming, where active investors and strategics speak directly to entrepreneurs about what they’re looking for, how they invest, and how startups can position themselves for success. The upcoming September event will feature deep dives into some of the most dynamic areas of healthcare innovation, featuring speakers from impact investors, corporate venture arms, Big Pharma, family offices, and more.

Impact Investors & Venture Philanthropy Panel

The Role of Impact Investing in the Healthcare Ecosystem

Impact investors and venture philanthropists are playing a growing role in backing early-stage healthcare ventures, especially those addressing health equity and underserved areas. In this panel, leaders in the field will discuss how they define and measure impact, what they look for in mission-driven ventures, and how they work with founders to align values with milestone-based progress. Attendees will gain insight into how this capital is deployed to catalyze innovations that go beyond traditional ROI.


Mental & Behavioral Health Panel

Investing in Solutions for Higher Quality of Life and Wellbeing

With 1 in 8 people globally affected by mental disorders, demand for novel solutions in behavioral health continues to grow. This panel features investors who are actively backing companies developing digital tools, neurotechnologies, care delivery innovations, and novel therapeutics. Panelists will explore challenges such as stigma, reimbursement, and regulation—along with what it takes for startups to stand out in this vital and rapidly evolving market.


Oncology Innovation Panel

Latest Scientific Breakthroughs and Future Outlook

Oncology continues to attract robust investor interest, yet the bar for scientific rigor and differentiation is high. This session gathers investors focused on oncology diagnostics, therapeutics, and platforms to discuss what excites them in the current landscape and what it takes to succeed. Topics include scientific novelty, clinical de-risking, commercial potential, and where the next wave of oncology innovation may arise.


Corporate VC Panel

Venture and Innovation Arms Making Strategic Investments

Corporate VCs offer much more than capital, they bring strategic alignment, deep expertise, and long-term partnership opportunities. In this session, leaders from CVC arms of major pharma, biotech, and medtech companies will discuss how they source and evaluate early-stage deals, what startups should expect post-investment, and how founders can navigate alignment with a corporate parent. This panel is essential for startups seeking strategic investors.


Diagnostics Panel

Investing in Innovations for Preventative and Personalized Care

As diagnostics become increasingly central to precision medicine and population health, investors are paying close attention. Panelists in this session will discuss how they evaluate new diagnostic technologies, from regulatory and reimbursement outlooks to commercial differentiation and unmet need. For entrepreneurs developing platforms in oncology, infectious disease, or chronic conditions, this discussion will provide actionable guidance on positioning and funding strategies.


Partnering with Big Pharma Panel

What Startups Need to Know to Get on Big Pharma’s Radar

Securing a partnership with Big Pharma can be a transformative milestone. This panel features business development and venture leaders from leading pharmaceutical companies who will share what they look for in early-stage collaborations. Learn how they assess risk, stage readiness, and strategic fit—plus how startups can build compelling cases for co-development, licensing, or investment.


Family Offices Panel

Perspectives on Early-Stage Investments

Family offices have become increasingly visible in early-stage healthcare deals, often offering patient capital and values-driven investment strategies. This panel will unpack how these investors approach opportunity evaluation, what sets them apart from traditional VCs, and how they support portfolio companies beyond capital. Attendees will also hear practical advice for engaging family offices and building meaningful relationships.


Whether you’re developing breakthrough diagnostics, therapeutics, platforms, or care delivery solutions, the RESI Boston investor panels offer a unique opportunity to hear directly from the funders shaping the future of healthcare.

Interested in sharing your insights at RESI? Reach out to join our speaker lineup!

Register by July 11 to lock in Super Early Bird Rates and save $300. Secure your spot today and join 400+ investors and strategic partners this September in Boston.

Introducing BD Assist: LSN Sets Up the Meetings For Your Global Investor Roadshow

24 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) pioneered investor engagement through its RESI Conferences, global investor database, and entrepreneurial education programs. LSN is taking a significant leap forward with the launch of BD Assist, a full-service investor outreach and meeting management product designed to augment and complement your in-house BD efforts.

With BD Assist, LSN aids in the tedious task of booking meetings with your partner targets:

  • LSN Labs AI Agent will optimize your messaging for outreach.
  • Identify and prioritize well-matched capital and licensing partners
  • Conduct coordinated outreach
  • Schedule and confirm investor meetings on your behalf

The product development, regulatory, and operational complexities of running a life science company are already challenging enough. BD Assist removes one of the most tedious but significant burdens: finding, securing, and managing investor meetings.

Why LSN Is Uniquely Positioned to Do This
LSN combines getting the right target list, a proven canvassing and follow-up methodology, and a dedicated outreach team to deliver results. LSN is a well-known, trusted, and credible entity in the partnering space. We know what life science investors are looking for and which meetings they’ll take. Over the past decade, we’ve taught hundreds of startups how to craft their story, manage outreach, and execute CRM-powered campaigns. The results are real; see our Australian accelerator cohort, where 90% of companies secured funding or strategic partnerships.

BD Assist takes on the daily work of driving your campaign forward. We handle the outreach, schedule your meetings, manage follow-up, and sync it all to your CRM in real time. You stay focused on the science, and we set up the business development meetings. If you’re raising capital or licensing in the next 12 months, BD Assist is your opportunity to launch a turnkey global campaign without hiring a whole BD team.

Ready to activate your global roadshow?
Contact us at salescore@lifesciencenation.com to get started.

The RESI Boston June 2025 Program Guide Release

10 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022The official program guide for RESI Boston, June 2025 is now available! Redefining Every Stage of Investment (RESI) is built to connect life science and healthcare innovators with a global network of investors representing a wide range of funding strategies, from Seed through Series B and beyond.

This guide provides an overview of what to expect throughout the conference, detailing all of the content and layout for our in-person event on June 16th. Inside, you’ll find the full agenda, speaker bios, panel descriptions, and key information to help you navigate your RESI experience. Whether you’re participating in investor meetings, pitch sessions, workshops, or ad hoc networking, this guide is your resource to stay informed and get the most out of RESI Boston.

Access the full guide here:

Introducing the Investor Judges for the Innovator’s Pitch Challenge at RESI Boston 

10 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston takes place on June 16, and Life Science Nation is pleased to announce the investor judges participating in this event’s Innovator’s Pitch Challenge (IPC). With more than 50 companies presenting across 14 sessions, the IPC offers life science startups a high-impact opportunity to gain visibility, pitch directly to active investors, and receive valuable feedback in real time.

Each session will feature investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Following every pitch, judges will lead a live Q&A to assess the opportunity and share insights from the investor perspective.

Every IPC company will also have a dedicated table in the RESI Exhibition Hall, making it easy for attendees to connect with founders and learn more.

All registered attendees will be invited to vote online for their favorite companies, and the Top 3 companies will be announced at the end of the day’s cocktail reception. Winners will receive a prize and be featured in an upcoming issue of the LSN newsletter.

Scroll down to see which investors will serve as judges for this year’s IPC:

John Abeles
John Abeles
General Partner
Northlea Partners
Chris Aleong
Chris Aleong
VP
BioIdeations
Christina Ansted
Christina Ansted
Sr. Managing Partner
RCP Venture Capital
Jit Basak
Jit Basak
Investor
Launchit Ventures
Jay Batchu
Jay Batchu
Entrepreneur in Residence
Xontogeny
Randy Berholtz
Randy Berholtz
Sr. Advisor
Mesa Verde Venture Partners
Jeff Berman
Jeff Berman
Managing Partner & Co-Founder
Big Tree Innovation Fund
Kalyan Chakravarthy
Kalyan Chakravarthy
Sr. Manager, External Innovation
Ipsen S.A.
Jo Chaturvedi-Durant
Jo Chaturvedi-Durant
Sr. Investor & Venture Partner
VU Venture Partners
Shailesh Chavan
Shailesh Chavan
Managing Partner
Transatlantic Life Science Venture
Nicolas Cindric
Nicolas Cindric
Partner
Yahara Ventures
Javier Coindreau
Javier Coindreau
General Partner (Boston)
Sila B Health Ventures
Bettina Ernst
Bettina Ernst
Director
BERNINA BioInvest
Alex Fair
Alex Fair
Managing Partner
Medstartr Capital
Dimitra Georganopoulou
Dimitra Georganopoulou
Managing Director
Qral Ventures
Serban Georgescu
Serban Georgescu
Due Diligence Chair
Mass Medical Angels
Ken Grise
Ken Grise
Principal
Sixty Degree Capital
Marco Gulla
Marco Gulla
Investment Associate
Health Technology Holding (HTH)
George Hong
George Hong
Investor
H Advisor Group
Guanghui Hu
Guanghui Hu
Venture Partner & CEO
Viva BioInnovator
Kristin King-Jankiewicz
Kristin King-Jankiewicz
Member & Head of Group Management
Boston Harbor Angels
Claire Leurent
Claire Leurent
Managing Director
AbbVie
Vivian Li
Vivian Li
SA
K2 Venture Partners
Ali Malihi
Ali Malihi
President
Back Bay Group
Nune Martiros
Nune Martiros
Sr. Associate
Paladin Capital Group
Jim McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels
Ralph Morales III
Ralph Morales III
Venture Partner / Executive-in-Residence
Aquillius Ventures
Jose Navarro
Jose Navarro
Scientific Director & Partner
quadraScope Venture Fund
Lizzie Ngo
Lizzie Ngo
Principal
Longwood Fund
Yoichi Omae
Yoichi Omae
BD Director
Asahi Intecc USA Inc
Soyoung Park
Soyoung Park
General Partner
1004 Venture Partners
Chandra Ramanathan
Chandra Ramanathan
VP and Head of External Innovation, Life Sciences Innovation Group
Danaher Corporation
Nans Rivat
Nans Rivat
VP
PACE Healthcare Capital
Shreya Sawant
Shreya Sawant
Venture Partner
Aquillius Ventures
Pranav Seshadri
Pranav Seshadri
Investor
T.Rx Capital
Jason Shieh
Jason Shieh
Partner/Co-Founder
HelixPoint Capital
Oliver Sims
Oliver Sims
Investment Manager
Octopus Ventures
Alex Spicer
Alex Spicer
M&A Associate
SERB Pharmaceuticals
Sri Sriadibhatla
Sri Sriadibhatla
Director, Healthcare Investment Group
Ben Franklin Technology Partners of Southern Pennsylvania
Isaac Stoner
Isaac Stoner
EIR
Slater Technology Fund
Asad Taherbhoy
Asad Taherbhoy
Angel Investor
Angel Star Ventures
Wei Tao
Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels
Vince Wong
Vince Wong
CEO and President
BioCrossroads
Chris Yoo
Chris Yoo
General Partner and Managing Director
Xcellerant Ventures
Doug Zingale
Doug Zingale
Co-Founder & Managing Partner
Blue Goose Capital
Patrick-Cooke
Patrick Cooke, PhD
Associate
Merck Digital Sciences Studio
SERB Pharmaceuticals
Samuel Freedman
M&A Analyst
SERB Pharmaceuticals

RESI Boston June Investor Panelists 

3 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The full-day panel schedule at RESI Boston on June 16 will spotlight the top investment themes shaping the life science ecosystem. From family offices and health systems to pharma and AI-focused funds, the RESI stage will feature active investors across the spectrum sharing how they evaluate opportunities and what’s driving their deal flow.

Panels will cover key topics such as sector-specific outlooks, alternative funding sources, emerging technologies, and cross-border strategy. These sessions are designed for entrepreneurs to better understand investor priorities, refine their pitch, and build lasting relationships in the industry.

RESI Boston takes place in person at the Westin Copley Place on June 16, with virtual partnering continuing June 17–18 and June 23. Whether you’re attending in person or virtually, don’t miss this opportunity to hear directly from investors who are actively shaping the future of healthcare innovation.

Join the panelists below at RESI Boston June:

John Abeles
John Abeles
General Partner
Northlea Partners
John Abeles
Salma Al-Zu’bi
Investment Principal
Hikma Ventures
Marc Appel
Marc Appel
Managing Partner
Pacific Bridge NY
Caleb Bell
Caleb Bell
Advisor
Beyond Next Ventures
Ethan Berg
Ethan Berg
Managing Partner
G4 Investments, LLC
John Boyce
John Boyce
Managing Director & Co-Founder
28 Capital
Dirk Büscher
Dirk Büscher
Sr Director Grifols Innovation & New Technologies
Grifols
Danny Carbonero
Danny Carbonero
Investor
PsyMed Ventures
Nicolas Cindric
Nicolas Cindric
Partner
Yahara Ventures
Leo Cui
Leo Cui
Partner
FoundersX
Bettina Ernst
Bettina Ernst
Director
BERNINA BioInvest
Marc Estigarribia
Marc Estigarribia
Managing Director
MSQ Ventures
Eileen Flowers, PhD
Eileen Flowers, PhD
Director, Technology Development & Licensing
Memorial Sloan Kettering Cancer Center
Ser-Chen Fu
Ser-Chen Fu
Partner
Pacific 8 Ventures
Ayah Hamdan
Ayah Hamdan
Director & Ventures, Health
Plug and Play Ventures
Zizi Imatorbhebhe
Zizi Imatorbhebhe
CEO & Executive Partner
Bios Health Group
Cheryl Kuai
Cheryl Kuai
Managing Director
Sixty Degree Capital
Michael Langer
Michael Langer
Founder & Managing Partner
T.Rx Capital
John Leader
John Leader
Partner
Green Park & Golf Ventures
Chloé Lepretre
Chloé Lepretre
Head of Global R&D Search & Evaluation
Servier
Andrew Merken
Andrew Merken
Shareholder
Polsinelli PC
Fiona Miller
Fiona Miller
Managing Partner
quadraScope Venture Fund
Ravi Mistry
Ravi Mistry
Venture Partner / Officer & Founding Team Member
3i Partners
Ralph Morales III
Ralph Morales III
Venture Partner / Executive-in-Residence
Aquillius Ventures
Daniel O'Mahony
Daniel O’Mahony
Partner
Seroba Life Sciences
John Parker
John Parker
Founder & Managing Director
Springhood Ventures
John Pennett
John Pennett
Angel Investor
Mid Atlantic Bio Angels
Prashant Shah
Prashant Shah
Partner
O2h Ventures
Jeremy Sohn
Jeremy Sohn
Managing Partner
P74 Ventures
Nicolas Stalder
Nicolas Stalder
Sr. Investment Manager
Debiopharm Innovation Fund
Adam Steinert
Adam Steinert
CTO
Yahara Ventures
Jeff Stinson
Jeff Stinson
Director
HealthTech Arkansas
Alex Strasser
Alex Strasser
Sr. Associate
Apollo Health Ventures
Bob Sweeney
Bob Sweeney
Principal & Co-Founder
Global Health Impact Fund
Thomas Thornton
Thomas Thornton
Vice President, Innovation, Jefferson Ventures
Jefferson Health
John Tremblay
John Tremblay
Investor
Launchpad Venture Group
Mark Vreeke
Mark Vreeke
Co-Founder
Chemical Angel Network
Sally Wang Liang
Sally Wang Liang
Managing Partner
Xpanse Venture
Don Zinn
Don Zinn
US Vice President US Business
Crossject

Meet the Finalists: 14 Sessions of Cutting-Edge Innovation at the RESI Boston June Innovator’s Pitch Challenge 

28 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge (IPC) returns to RESI Boston this June with a robust lineup of 14 pitch sessions featuring early-stage companies from across the life science spectrum. Finalists span core sectors including Medical Devices, R&D, Therapeutics, Diagnostics, and Digital Health. Several sessions will highlight technologies with a specific focus—such as surgical applications, oncology, gene therapy, and advanced delivery systems—providing a deeper look at high-impact areas of healthcare innovation.

These sessions offer RESI attendees the opportunity to explore a wide range of breakthrough solutions and meet the entrepreneurs behind them. Each company will present to a panel of active investors and strategic partners, engaging in live Q&A and receiving valuable feedback. Beyond the pitch stage, IPC finalists will also be featured in the RESI exhibition hall, where they will host tables to continue conversations and meet one-on-one with potential partners and investors.

IPC voting will take place online throughout the conference, with attendees selecting their top picks. The three companies with the highest number of votes will be recognized at the conclusion of the event and featured in Life Science Nation’s Next Phase newsletter. In addition to this recognition, winners will receive complimentary registration to future RESI conferences.

More than just a pitch event, the IPC is designed to help fundraising companies gain visibility, validate their approach, and connect with a global network of partners in the early-stage life science ecosystem.

See the full list of pitching companies:

BioMetas and Life Science Nation Form Global Accelerator Alliance to Transform Early-Stage Therapeutics 

20 May

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

BioMetas Group, a leading preclinical contract research organization (CRO), and Life Science Nation (LSN), a global leader in life science commercialization and capital formation, have joined forces to launch a strategic cross-border accelerator alliance. This partnership aims to reshape how early-stage therapeutic startups are sourced, developed, and scaled, combining scientific execution with commercialization readiness to build globally fundable companies.

The new alliance links BioMetas Innovator (Singapore) and LSN Labs (Boston) into a fully integrated platform. Together, they will select and support elite early-stage therapeutic assets from their shared networks in North America, APAC, and Europe.

At the heart of the partnership is a joint service-for-equity model designed to address one of the most persistent challenges in early-stage biotechs: the capital gap between scientific promise and commercial viability. By providing critical services in exchange for equity, both accelerators aim to empower promising startups that might otherwise stall due to limited funding.

“The early-stage ecosystem often fails not because of science, but because of timing, execution, and lack of access,” said Simon Hua, Founder of BioMetas. “By partnering with LSN, we combine rigorous preclinical testing with a global commercialization platform to help these companies reach key inflection points and engage the world.”

BioMetas will deliver milestone-based development and scientific validation through its CRO services. With a team of over 150 experienced scientists and deep experience across oncology, immunology, and other diseases, BioMetas provides a full suite of preclinical services, including in vivo / in vitro pharmacology, PK/PD modeling, biomarker discovery, protein science, and IND enabling package studies. These capabilities are offered under a service-for-equity structure, allowing startups to generate high-value, decision-driving data before raising their first institutional capital.

LSN will provide its entrepreneurial education curriculum, global partnering and roadshow training, access to its proprietary investor and licensing partner database, BD Assist meeting scheduling, and the tools needed to prepare and execute global roadshow campaigns. Companies will also gain exposure by participating in the RESI global partnering conferences that connect startups with capital investors and business development teams annually at five international events.

Launching with a 20-company pilot cohort, the alliance will apply a shared diligence framework to evaluate scientific potential and commercial readiness. Participating startups will gain access to targeted development services, curated partner matching, and cross-border exposure to capital and licensing partners.

Too often, scientific founders are left to navigate commercialization alone. The new program provides a structured bridge from discovery to global market engagement, giving founders the tools, systems, and support to thrive.

“This alliance creates a new engine for global therapeutic innovation,” said Dennis Ford, Founder of Life Science Nation. “It’s not just about helping scientists become entrepreneurs — it’s about giving them the infrastructure, the partners, and the roadmap to succeed on a global stage.”

This initiative marks the first step in building a scalable venture-building infrastructure for early-stage therapeutics. As the platform expands, startups will gain access not only to services and education, but to a growing ecosystem of capital partners and strategic collaborators committed to advancing breakthrough innovation.

Media Contact:
info@lifesciencenation.com
www.lifesciencenation.com | www.biometasgroup.com